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Abstract 
The distinction between episodic viral wheeze (EVW) and multiple trigger wheeze (MTW) is 
used to guide management of preschool wheeze. It has been questioned whether these 
phenotypes are stable over time. We examined the temporal stability of MTW and EVW in two 
large population-based cohorts.  
We classified children from the Avon Longitudinal Study on Parents and Children (N=10,970) 
and the Leicester Respiratory Cohorts (LRC, N=3,263) into EVW, MTW and no wheeze at ages 
2, 4 and 6 years based on parent-reported symptoms.  Using multinomial regression, we 
estimated relative risk ratios (RRRs) for EVW and MTW at follow-up (no wheeze as reference 
category) with and without adjusting for wheeze severity.   
Although large proportions of children with EVW and MTW became asymptomatic, those that 
continued to wheeze showed a tendency to remain in the same phenotype: Among children with 
MTW at 4 years in LRC the adjusted RRR was 15.6 (95% CI: 8.3, 29.2) for MTW (stable 
phenotype) compared to 7.0 (2.6, 18.9) for EVW (phenotype switching) at 6 years. The tendency 
to track was weaker for EVW and from 2-4 years. Results were similar across cohorts. 
This suggests that MTW and, to a lesser extent, EVW track regardless of wheeze severity.   
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Introduction 
There is debate whether recurrent wheezing in young children represents a single disease entity, 
“childhood asthma”, or a heterogeneous group of disorders, referred to as asthma “phenotypes”. 
Numerous attempts have been made to distinguish phenotypes.1-3 A commonly used 
classification is the distinction between episodic viral wheeze and multiple trigger wheeze.4, 5 
Episodic viral wheeze (EVW), also called exclusive viral wheeze, characterises children who 
wheeze only during respiratory infections. During the intervals between colds, these children are 
asymptomatic. EVW is frequent in infancy and preschool years, less prevalent in older children,6 
and has also been described in adults.7 Multitrigger wheeze (MTW) more closely resembles 
classical asthma.8 Children with MTW also wheeze between respiratory infections in response to 
a variety of factors, including allergens, exercise, laughing or crying, strong smells or certain 
foods or drinks.9 MTW is more strongly associated with lung function abnormalities8 and 
atopy.10 While most children with EVW become asymptomatic, MTW tends to persist.11, 12 This 
two-phenotype model has been used to guide management of preschool wheeze.9, 13-16 For 
instance, a taskforce of the European Respiratory Society (ERS) recommended using inhaled 
corticosteroids for maintenance treatment of MTW, but montelukast for EVW.9     
The distinction between EVW and MTW and its usefulness for the management of preschool 
wheeze has been challenged.17, 18 Garcia Marcos and colleagues suggested that the two 
phenotypes merely reflect the ends of a severity spectrum with MTW representing more severe 
wheeze.19 Severity of wheeze, in particular frequency of episodes, strongly predicts long-term 
prognosis.12, 20, 21 It has also been questioned whether these phenotypes are sufficiently stable 
over time to represent clinically meaningful entities.22, 23 In an update of their recommendations 
in 2014, the ERS taskforce pointed out that wheeze patterns in young children vary over time 
and with treatment, rendering the distinction between EVW and MTW difficult in many 
patients.17 Consequently, inhaled corticosteroids remained the first-line treatment for MTW, but 
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were also recommended for patients with frequent or severe EVW. The taskforce concluded that 
future research should focus on disease severity in addition to phenotypes.17 
The current study used longitudinal data on wheezing at ages 2, 4, and 6 years from two large 
population-based birth cohorts, to examine the stability of MTW and EVW over time, and the 
degree to which stability was explained by differences in wheeze severity.  
Material and methods 
Study populations  
ALSPAC is a longitudinal population-based birth cohort study that recruited 14,541 pregnant 
women resident in Avon, UK, with expected dates of delivery between April 1991 and 
December 1992. There were 14,062 live born children. The study has been described in detail 
elsewhere.24 Each year up to children’s age of 8 years, the study mothers were sent child health 
questionnaires including detailed questions on respiratory symptoms. Ethical approval was 
obtained from the ALSPAC Ethics and Law Committee and from Local Research Ethics 
Committees. 
The Leicestershire 1998-b respiratory cohort (LRC) consists of a population-based random 
sample of 4300 children born between May 1996 and April 1997 in Leicestershire, UK. It is, 
described in detail elsewhere.25 Perinatal routine data were obtained from Leicestershire Health 
Authority Child Health Database and mothers were sent questionnaires including detailed 
questions on respiratory symptoms in 1998, 1999, 2001, 2003, 2006 and 2010. The study was 
approved by the Leicestershire Health Authority Research Ethics Committee. 
We include all children in both cohorts whose parents responded to a questionnaire sent at age 2, 
4, or 6 years (30, 57 and 81 months’ questionnaires in ALSPAC). 
Definition of wheeze phenotypes 
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The questions used to address wheeze or whistling in the previous 12 months (current wheeze) 
were similar in both cohorts (Table 1). Children were assigned to the EVW phenotype if they 
reported current wheeze in the previous 12 months with infections as a trigger and no other 
triggers (Table 1). Children with current wheeze in the previous 12 months reporting a trigger 
category other than infections were assigned to MTW. Children with current wheeze who could 
not be assigned either to EVW or MTW were designated non-classifiable. 
Information on wheeze severity 
We defined the following indicators of wheeze severity based on symptoms in the previous 12 
months: frequent wheeze attacks (≥3 in ALSPAC, ≥4 in LRC), shortness of breath during wheeze 
attacks, sleep disturbed due to wheezing, speech limited to 1-2 words at a time between breaths due to 
wheeze (ALSPAC only), wheeze interfering with child’s daily activities (LRC only). The questions 
used to assess this information and the definitions of severity indicators are provided in the 
supplementary Table S1. 
Statistical analysis 
We carried out the following analysis steps: 
a) We computed the prevalence of current wheeze, EVW and MTW at ages 2, 4, and 6 years.  
b) At each age, we assessed the association between wheeze phenotypes and dichotomous 
indicators of severity (supplementary Table S1) by calculating odds ratios (OR) for MTW vs. 
EVW comparing severe with less severe wheeze using logistic regression.  
c) For each age interval, 2-4, 4-6, and 2-6 years, we assessed whether wheeze phenotype at the 
first time point (baseline) predicted current wheeze at the later time point (follow-up). We used 
logistic regression to estimate odds ratios (OR) for current wheeze at follow-up, comparing 
children with EVW and MTW at baseline with those without wheeze.  
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d) For each age interval, we assessed whether children tended to have the same wheeze 
phenotypes at follow-up as they did at baseline. We first calculated the probability for these 
categories at follow-up given the category at baseline. Using multinomial logistic regression, we 
then estimated relative risk ratios (RRR) for EVW and MTW at follow-up respectively 
comparing these phenotypes with no wheeze at baseline. We adjusted regression models for 
symptom severity (original variables, not dichotomised) at baseline to determine whether the 
phenotypes at baseline predicted the phenotypes at follow-up independent of severity. In 
separate models we additionally adjusted for sex, ethnicity (white, other), maternal smoking 
during pregnancy, older siblings (yes/no), crowding (>1 person/room) and pet ownership. The 
RRRs compare the risk ratio for phenotypes at follow-up (probability for having the phenotype 
divided by probability of having no wheeze) in children of a given phenotype at baseline (EVW, 
or MTW) to children with no wheeze at baseline. We also tested for the equality of RRRs 
between EVW and MTW at baseline. Such equality implies absence of tracking. For instance, 
equality of RRRs for EVW at follow-up means that, after excluding children with MTW at 
follow-up, those with EVW and MTW at baseline are equally likely to have EVW at follow-up.  
Results  
Of the 14,062 live born children recruited in ALSPAC, we included 10,970 (78%) for whom 
information on wheeze was available for at least one time point (age 2, 4, or 6 years). 
Information on wheeze was provided for 9953, 9391 and 8393 children at the ages of 2, 4 and 6 
years respectively (Table 2).  Similarly, of the 4300 children in the LRC (1998-b cohort), we 
included 3263 (76%) and information on wheeze was reported for 2355, 2609 and 2077 at ages 
2, 4, and 6 years respectively.  
The cohorts differed with respect to ethnicity and socio-economic conditions (Table 2). In 
ALSPAC, 97% of the children were white. In the LRC, 85% were white and 15% of south Asian 
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origin. Households in the LRC tended to be more crowded, and maternal smoking and pet 
ownership was less common than in ALSPAC. The proportions of children whose mothers 
smoked during pregnancy, who had older siblings or who lived in crowded homes were lower in 
children who participated in only 1-2 surveys compared to those who participated in all 3, and 
lower still in children excluded from analyses (Supplementary Table S2). Maternal smoking 
during pregnancy was more common among children with MTW than EVW (Supplementary 
Table S3).    
Prevalence of current wheeze and wheeze phenotypes at ages 2, 4 and 6 years 
Prevalence of current wheeze in ALSPAC was 23% at age 2 years, and decreased to 13% at age 
6 years (Table 2). In LRC, current wheeze decreased similarly from 23% at age 2 to 16% at age 
6 years. The relative frequency of the two phenotypes were remarkably similar in both cohorts. 
At age 2, 45% of all classifiable wheezers in ALSPAC (44% in the LRC) were defined as EVW; 
this decreased to 36% (32%) at age 4 and 30% (24%) at age 6.  
Associations between wheeze phenotypes and indicators of wheeze severity 
Severity of wheezing illness as defined by the five indicators (frequency of attacks, shortness of 
breath, sleep disturbance, interference with activities and speech limitation) was higher for 
MTW than for EVW (Table 3). The difference between phenotypes was larger in LRC than in 
ALSPAC. For example, at age 2, the odds ratio (OR) for having MTW rather than EVW 
comparing children with frequent episodes of wheeze to those with less frequent episodes was 
2.7 (95% CI: 2.2, 3.2) in ALSPAC and 6.5 (4.1, 10.4) in LRC. In the LRC, differences between 
the two phenotypes became more distinct (larger odds ratios) with age.  
Risk of later wheeze in children with episodic viral wheeze and multiple trigger wheeze 
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The risk of having current wheeze two or four years later was higher for MTW than for EVW in 
both cohorts (Supplementary Table S4 and S6). In the ALSPAC cohort, the OR for wheeze at 
age 4 was 7.8 (95% CI: 6.5, 9.3) for children with EVW at age 2 years, and 12.5 (10.6, 14.8) for 
those with MTW, compared to children who did not wheeze. Respective ORs were 3.7 (2.6, 5.3) 
and 9.9 (7.2, 13.5) in the LRC. Prediction of later wheeze was stronger from age 4 to 6: In 
ALSPAC, ORs were 26.6 (22.2, 32.1) for MTW and 11.9 (9.5, 14.8) for EVW at baseline 
(Table S4, crude OR). When the regression models were adjusted for wheeze severity, the 
difference in prognosis between the two phenotypes diminished somewhat, particularly in 
ALSPAC (Table S4, Adj. OR). ORs for current wheeze 4 years later (prediction from 2 to 6 
years) were lower compared to the 2-year prediction intervals (Table S6).  
Likelihood of keeping or switching wheeze phenotype 
The proportion of children remaining in their phenotype or transitioning to another phenotype 
was similar in the two cohorts (Supplementary Table S5 and Figure 1). Among ALSPAC 
children who had EVW at 2 years and who had a classifiable wheezing pattern 2 years later, 
57% became asymptomatic, while 21% still had EVW and 22% had developed MTW. Among 
children with MTW at age 2, 45% became asymptomatic, 45% remained MTW and only 10% 
were reclassified to EVW.  
Despite considerable proportions of children remitting or changing phenotype, multinomial 
logistic regressions showed a tendency of phenotypes to track: relative risk ratios (RRR) were 
consistently higher for remaining in the same phenotype than for phenotype switching (Table 4 
and supplementary Tables S5 and S7). Among children with EVW at age 2 years in ALSPAC, 
the crude RRR was 9.4 (95% CI: 7.4, 11.9) for EVW (stable phenotype) but 7.7 (6.1, 9.7) for 
MTW (phenotype switching) at 4 years. Among children with MTW at 2 years the tendency for 
tracking was much stronger with a RRR for later MTW and EVW of 20.5 (16.8, 24.8) and 5.9 
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(4.4, 7.8) respectively. Tracking was stronger for both phenotypes from age 4 to 6 years and was 
strongest for MTW: RRRs 44.9 (35.4, 56.9) and 27.3 (18.9, 39.6) in ALSPAC and LRC 
respectively. Although the RRRs diminished after adjustment for severity, they remained 
considerable higher for remaining in the same phenotype than switching, particularly for MTW 
(Table 4, Adj. RRR). Despite the larger proportions of children becoming asymptomatic, RRRs 
for the 4 year period from age 2-6 years still reveal a tendency of phenotypes to track 
(Supplementary Table S7). Additionally, adjusting regression models for sociodemographic 
variables and early environmental exposures only led to marginal changes in estimated RRRs 
(results not shown).   
Statistical tests also support phenotype tracking. The p-values for equality of RRRs between 
EVW and MTW at baseline are all <0.01 except in LRC for EVW at follow-up (Table 4). These p-values 
remain low after adjusting for symptom severity.  
Discussion 
Using prospectively collected data from two independent population-based cohorts, our study 
found that children with MTW and EVW whose wheeze persisted over two year periods (from 
ages 2-4 and 4-6 years) showed a tendency to remain in the same phenotype. This tracking was 
stronger for MTW than for EVW and was only partially explained by reported symptom 
severity. This supports the hypothesis that EVW and MTW represent distinct disease entities 
rather than different ends of a severity spectrum. Our study also confirms that a high proportion 
of early wheeze remits (approximately 60-70% of EVW and 40-45% of MTW). Despite 
differences in study design and methodology, results from the two cohorts were closely similar.  
Strengths and weaknesses of the study 
Our study was based on two large, population-based cohort studies that assessed wheezing 
prospectively. This provided large representative samples and enabled us to use phenotype 
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definitions that are consistent over time. Both cohorts have information on frequency and 
severity of wheeze, which allowed us to assess whether differences in severity explained the 
tendency for phenotypes to track. Although the two cohorts use different measures of severity, 
the relationships between these markers and phenotypes are similar in both cohorts.  
Phenotype definitions were based entirely on parent reports of symptoms during the previous 12 
months. Parental assessment may be unreliable not only for the presence of wheeze, but also for 
wheeze severity and the presence of viral infections. In both cohorts, we defined phenotypes 
indirectly based on individual triggers of wheeze reported. Non-viral triggers may have been 
underreported because not all possible triggers were specifically addressed. However, in LRC, 
parents’ direct assessment of children’s wheezing pattern shows good agreement with our 
phenotype definitions and does not suggest under reporting of non-viral triggers (supplementary 
Table S8). EVW may have been underreported in ALSPAC, as wheeze with colds was not an 
explicit response option (Table 1). This may explain the larger proportion of non-classifiable 
wheeze in ALSPAC. Although both cohorts were large and population-based, not all children 
participated in each survey. The samples with information available at baseline and follow-up 
were thus somewhat reduced and not fully representative of the entire cohorts. 
How do the results compare to other studies? 
Our study is the largest study investigating the temporal stability of MTW and EVW and the 
only one to statistically test whether these phenotypes track. Furthermore, it is the only study to 
investigate whether this tracking is explained by symptom severity, a known risk factor for the 
persistence of wheeze. To our knowledge, only four studies have assessed the stability of EVW 
and MTW over time.22, 23, 26, 27 Study populations were smaller than either of our two cohorts. 
The results of these studies are summarised in the supplementary Table S9. Despite differences 
in study population and design, the proportions of children becoming asymptomatic or changing 
phenotype were broadly comparable to those in our study. Two of the four studies investigated 
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both EVW and MTW and one showed, in agreement with ours, that the proportion of children 
remaining in the same phenotype was larger for MTV than for EVW,22 while the other study 
showed greater stability for EVW.23 However, none of these studies used regression modelling 
to investigate the tendency of phenotypes to track or the extent to which such a tendency might 
be explained by symptom severity. 
Our observation that the proportion of children with MTW increases with age while EVW 
decreases with age is in line with other studies.3, 6, 11, 28, 29 An early cross-sectional study showed 
a positive correlation of age with allergy and exercise as triggers of asthma and a negative 
correlation with respiratory infections.28 Using partly overlapping data from the LRC, we have 
previously shown a decrease in the proportion of infections as an exclusive trigger among 
children with current wheeze from 57% at age 1 to 21% at age 9 years, while the proportion of 
children also reporting other triggers increased correspondingly.29   
Similarly, our findings that MTW is associated with more severe wheeze than EVW confirms 
findings from other studies.6, 30. Cross-sectional surveys in Aberdeen reported less frequent 
episodes, and less night cough, shortness of breath and chest tightness in children with EVW 
compared to those with MTW.6, 30  
 
Interpretation 
In both cohorts, we found that, RRRs for EVW at follow-up were higher for children with EVW 
than for those with MTW at baseline, while RRRs for MTW at follow-up were higher for 
children with MTW at baseline. In the absence of any phenotype stability, we would have 
expected these RRRs to be equal. Instead, we found that children tend to remain in the same 
phenotype. We then explored if this was explained by differences in severity. If children with 
MTW on average had more severe disease, children classified as MTW at baseline would tend to 
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be reclassified as MTW at follow-up. This did in fact explain part of the difference, however the 
direction of our findings (higher RRRs for the same phenotype) remained the same after 
adjusting for severity. It is possible that results are still residually confounded by unmeasured 
severity. Although we corrected for a wide range of measures including frequency of episodes, 
shortness of breath, sleep and activity disturbance, these measures were based on parental report 
and may be inaccurate. We also cannot exclude that the observed stability of phenotypes was 
partially due to parent’s tendency to give the same, possibly inaccurate, answers to the same 
questions on symptoms over time. 
It should be noted that the stability of MTW observed in our study is not an artefact of its 
definition: It might for instance be objected that a child by definition becomes (and remains) a 
multiple trigger wheezer from the first time they wheeze in response to a non-viral trigger. 
However in our study, children were assigned to phenotypes based only on triggers of wheeze in 
the previous 12 months. Thus children wheezing only with colds during this period were 
classified as EVW regardless of whether they previously had MTW. This 12-month period of 
observation makes sense because interval symptoms may be seasonal and a classification based 
on shorter periods might be strongly affected by season. 
Also, our study shows that EVW in preschool children should not be equated with early transient 
wheeze. Indeed, after adjustment, EVW had a similar predictive value for later wheeze as MTW, 
particularly in the ALSPAC cohort (Supplementary Table S4) 
We suspect that the explanation of our finding is that differences in the underlying diseases 
processes other than severity cause some children to wheeze only during respiratory tract 
infections and other to be sensitive to other triggers. This reopens the possibility that certain 
therapies might indeed be more effective in certain phenotypes.9, 14, 16, 17  More research is 
needed to understand the underlying differences between EVW and MTW. Epidemiological 
studies should continue to distinguish between these phenotypes and better characterise them 
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regarding risk factors and prognosis. While translating such knowledge to clinical management 
will take time, our study suggests that we should not prematurely discard these phenotypes.  
Conclusions 
Using data from two large population based birth cohorts, we found that MTW and, to a lesser 
extent, EVW show a tendency to track from preschool to early-school age. While many children 
in both phenotypes become asymptomatic, those that continue to wheeze tend to remain in the 
same phenotype, though some phenotype switching does occur. The tendency to remain in the 
same phenotype was only partially explained by wheeze severity suggesting that there are other 
differences in the underlying disease processes of children with MTW and EVW.   
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Table 1: Questionnaire items and definitions of wheeze phenotypes in the Avon Longitudinal Study 
of Parents and Children (ALSPAC) and the Leicester Respiratory Cohort Study (LRC; cohort 
1998-b) 
ALSPAC LRC 
Current wheeze:  
1) “Since your child was (age at previous 
questionnaire) old has he/she had any periods 
when there was wheezing with whistling on his 
chest when he breathed?” (Yes/No)  
2) Has he/she had ‘wheezing’ in the last 12 
months? (Yes/No) 
Definition current wheeze: positive response to 1 
or 2  
Current wheeze:  
1) “Has your child had wheezing or whistling in 
the chest in the last 12 months?” (yes/no) 
 
 
 
 
Definition current wheeze: positive response to 
1 
Triggers of wheeze: 
3) “What do you think brings on the wheezing 
attacks? 
a) chest infection or bronchitis 
b) being in a smoky room 
c) cold weather 
d) I don’t know 
e) other (please describe)” 
 
Responses to 2e) were coded into following 
categories: 
f) infections (upper or lower RTI) 
g) allergic triggers (airborne allergens, foods and 
beverages) 
Triggers of wheeze:  
2) “In the last 12 months, has your child had 
wheezing or whistling in the chest during or 
soon after a cold or flu?” (yes/no) 
3) “In the last 12 months, has your child had 
wheezing or whistling in the chest even without 
having a cold or flu? (yes/no) 
 
4) “In the last 12 months did the following 
things cause wheezing in your child? 
a) exercise (playing or running)  
b) laughing, crying or excitement  
c) contact with pets or other animals  
d) pollen (grass, hay, trees, flowers) * 
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h) physical activities or intense emotions 
i) damp or cold indoor or weather conditions 
j) air pollution 
k) asthma (diagnosed, suspected, family history)  
l) other (e.g. hot temperature, irritants, teething) 
e) food or drinks”  
(answer categories for a-d: yes/no/don’t know) 
* only asked from age 4 years onward 
Phenotype definitions* 
EVW: (1 or 2) and (3a or 3f with no other 
categories reported) 
MTW: (1 or 2)  and (any of 3b, 3c, 3g-3j, or 3l) 
NCW: (1 or 2)  and (no response to 3, or 3d or 3k 
with no other categories reported) 
Phenotype definitions* 
EVW: 1 and (2 with no positive response to any 
of 3, 4a-4e) 
MTW: 1 and (any of 3, 4a-4e) 
NCW: 1 and (no positive response to any of 2, 
3, 4a-4e) 
Abbreviations: ALSPAC Avon Longitudinal Study on Parents and Children, LRC Leicestershire 
Respiratory Cohort 1998-b, EVW episodic viral wheeze, MTW multiple trigger wheeze, NCW non-
classifiable wheeze 
* Positive responses to listed questionnaire items required. 
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Table 2: Characteristics of study populations (Avon Longitudinal Study of Parents and Children 
and Leicester Respiratory Cohort Study) and prevalence of wheeze phenotypes at ages 2, 4 or 6 
years  
 Characteristics 
ALSPAC 
(n=10,970) 
LRC  
(n= 3,263) 
 n/N* % n/N* % 
Socio-demographic data     
Sex male 5680/10970 52 1692/3263 52 
Ethnicity white† 10266/10574 97 2761/3263 85 
Maternal smoking in pregnancy 2635/10879 24 460/2865 16 
Older siblings, ≥1 sibling 5778/10274 56 1837/2798 66 
Crowding, >1 person/room 2285/9406 24 1150/2852 40 
Pet ownership 5475/9805 56 1226/2903 42 
Wheeze at 2 years     
Current wheeze 2261/9953 23 533/2355 23 
of which‡:  EVW 752/1680 45 229/524 44 
   MTV  928/1680 55 295/524 56 
Wheeze at 4 years     
Current wheeze 1780/9391 19 504/2609 19 
of which‡:  EVW 519/1423 36 158/498 32 
   MTV  904/1423 64 340/498 68 
Wheeze at 6 years     
Current wheeze 1129/8393 13 330/2077 16 
of which‡:  EVW 236/779 30 79/325 24 
   MTV  543/779 70 246/325 76 
Abbreviations: ALSPAC Avon Longitudinal Study on Parents and Children, LRC Leicestershire 
Respiratory Cohort 1998-b, EVW episodic viral wheeze, MTW multiple trigger wheeze 
*n/N = number of children with positive characteristic/total number of children 
† In ALSPAC the remaining children are ethnically diverse while in Leicester 98-b the remaining 
children are of south Asian origin. 
‡ Denominator represents children with current wheeze that can be classified into EVW or MTV. 
Excludes children with non-classifiable wheeze (Table 1) and thus does not equal the number with any 
current wheeze. 
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Table 3: Association between wheeze phenotypes and symptom severity in ALSPAC and the LRC at ages 2, 4, and 6 years  
 ALSPAC LRC 
Indicators of symptom 
severity* 
EVW MTW 
OR† (95%CI) 
for MTW vs. 
EVW  
EVW MTW 
OR† (95%CI) 
for MTW vs. 
EVW  
Wheeze at age 2 years N=752 N=928  N=229 N=295  
Frequent attacks 39.7 63.6 2.7 (2.2, 3.2) 11.5 45.9 6.5 (4.1, 10.4) 
Shortness of breath 43.3 58.2 1.8 (1.5, 2.2) 39.9 76.2 4.8 (3.3, 7.0) 
Sleep disturbance NA NA NA 40.4 74.0 4.2 (2.9, 6.1) 
Interference with activities NA NA NA 38.0 73.6 4.5 (3.1, 6.6) 
Wheeze at age 4 years N=519 N=904  N=158 N=340  
Frequent attacks 45.3 74.0 3.4 (2.7, 4.3) 7.6 40.0 8.1 (4.3, 15.1) 
Shortness of breath 50.2 64.1 1.8 (1.4, 2.2) NA NA NA 
Sleep disturbance NA NA NA 41.7 71.3 3.5 (2.3, 5.2) 
Interference with activities NA NA NA 37.2 74.8 5.0 (3.3, 7.5) 
Wheeze at age 6 years N=236 N=543  N=79 N=246  
Frequent attacks 39.6 64.7 2.8 (2.0, 3.8) 5.1 41.1 12.9 (4.6, 36.4) 
Shortness of breath 53.0 61.3 1.4 (1.0, 1.9) NA NA NA 
Sleep disturbance 52.4 62.4 1.5 (1.1, 2.1) 43.0 67.4 2.7 (1.6, 4.6) 
Interference with activities NA NA NA 29.1 78.7 9.0 (5.1, 16.0) 
Speech limitation 8.1 13.4 1.8 (1.0, 3.0) NA NA NA 
Abbreviations: ALSPAC Avon Longitudinal Study on Parents and Children, LRC Leicestershire Respiratory Cohort 1998-b, EVW episodic viral wheeze, 
MTW multiple trigger wheeze. The data in the columns EVW and MTW represent prevalence (in %) of severity indicators among children with these 
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phenotypes. * Definitions of severity indicators are provided in the supplementary Table S1. † From logistic regression excluding children without wheeze 
or with non-classifiable wheeze 
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Table 4: Likelihood of keeping or switching the wheeze phenotype with age in children from ALSPAC and the LRC 
Age at 
baseline 
Age at 
follow-up 
Phenotype at 
baseline 
 
EVW at follow-up MTW at follow-up 
Crude RRR* 
(95% CI) 
P‡ Adj.  RRR*†  
(95% CI) 
P‡ Crude RRR* 
(95% CI) 
P‡ Adj.  RRR*†  
(95% CI) 
P‡  
ALSPAC           
2 4 No wheeze 1 0.004 1 <0.001 1 <0.001 1 <0.001 
  
EVW 9.4 (7.4, 11.9) 
 
4.6 (3.3, 6.4) 
 
7.7 (6.1, 9.7) 
 
3.2 (2.3, 4.3) 
 
  
MTW 5.9 (4.4, 7.8) 
 
2.2 (1.5, 3.3) 
 
20.5 (16.8, 24.8) 
 
6.2 (4.6, 8.4) 
 
4 6 No wheeze 1 0.002 1 <0.001 1 <0.001 1 <0.001 
  EVW 23.1 (16.5, 32.3)  8.0 (4.9, 13.1)  8.7 (6.2, 12.3)  2.0 (1.2, 3.3)  
  MTW 14.1 (9.8, 20.5)  3.3 (1.9, 6.0)  44.9 (35.4, 56.9)  6.7 (4.3, 10.4)  
LRC           
2 4 No wheeze 1 0.868 1 0.564 1 <0.001 1 0.004 
  EVW 4.9 (3.0, 8.0)  4.1 (2.2, 7.5)  3.1 (2.0, 4.9)  1.8 (1.0, 3.2)  
  MTW 5.1 (3.0, 8.7)  3.3 (1.4, 7.7)  12.9 (9.1, 18.2)  4.1 (2.1, 7.9)  
4 6 No wheeze 1 0.114 1 0.074 1 <0.001 1 <0.001 
  EVW 15.4 (8.1, 29.1)  15.5 (7.3, 32.9)  5.1 (2.8, 9.3)  4.0 (2.0, 8.0)  
  MTW 8.3 (4.2, 16.4)  7.0 (2.6, 18.9)  27.3 (18.9, 39.6)  15.6 (8.3, 29.2)  
Abbreviations: ALSPAC Avon Longitudinal Study on Parents and Children, LRC Leicestershire Respiratory Cohort 1998-b, EVW episodic viral wheeze, 
MTW multiple trigger wheeze, RRR relative risk ratio 
* Results from multinomial regression analysis. As an example for interpreting the RRR assume that among non-wheezers at baseline the risks for EVW and 
no wheeze at follow-up are 4% and 90% respectively. The risk ratio (RR) for EVW among non-wheezers is thus 0.044. If, in children with EVW at baseline 
the corresponding risks are 20% and 60%, i.e. RR=0.333, this would translate to a relative risk ratio (RRR) for EVW at follow-up of 7.5 (0.333/0.044). The 
regression analysis also included children with non-classifiable wheeze in a separate category (see Table 1) but results for this category are not reported. 
† Adjusted for symptom severity at baseline (frequent attacks, shortness of breath, sleep disturbance, interference with activities and speech limitation). 
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‡ P-values of tests for equality of RRRs between EVW and MTW at baseline. Such equality implies absence of tracking. For instance, equality of RRRs for 
EVW at follow-up means that, after excluding children with MTW at follow-up, those with EVW and MTW at baseline are equally likely to have EVW at 
follow-up. 
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Figure legend 
Figure 1. Transition probabilities from episodic viral wheeze (EVW) and multiple trigger wheeze 
(MTW) to EVW, MTW and no wheeze (NW) from 2 to 4 years and from 4 to 6 years in ALSPAC (A) 
and LRC (B). 
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Table S1 : Questions used to assess severity of wheeze and definition of severity indicators 
ALSPAC LRC 
Wheeze severity:  
1) In the past year has she/he had any periods 
when there was wheezing with whistling on 
his chest when he breathed? 
i. Yes 
ii. No 
b. How many separate times has this 
happened in the past 12 months? 
i. Once  
ii. Twice  
iii. 3-4 times 
iv. 5 or more times 
c. Was she/he breathless during any of these 
times? 
i. Yes for all 
ii. Yes for some 
iii. No not at all 
d. How often, on average, has your child’s 
sleep been disturbed due to wheezing in 
the past 12 months? 
i. Never woken with wheezing 
ii. Less than one night per week 
iii. One or more nights per week 
e. Has wheezing ever been severe enough to 
limit your child’s speech to only one or 
two words at a time between breaths in 
the past 12 months? 
i. Yes 
ii. No 
Wheeze severity:  
1) How many attacks of wheezing has your 
child had during the last 12 months? 
i. None 
ii. 1 to 3 
iii. 4 to 12 
iv. More than 12 
2) Do these attacks cause him/her to be short of 
breath? (only asked in 1999) 
i. Yes, always 
ii. Yes, occasionally 
iii. No, never 
3) In the last 12 months, how often, on average, 
has your child’s sleep been disturbed due to 
wheezing? 
i. Never woken with wheezing 
ii. Less than one night per week 
iii. One or more nights per week 
4) In the last 12 months, how much did 
wheezing interfere with your child’s daily 
activities? 
i. Not at all 
ii. A little 
iii. A moderate amount 
iv. A lot 
Definition of severity indicators:  
Frequent attacks: 1.b.iii or 1.b.iv (≥3 attacks) 
Shortness of breath: 1.c.i or 1.c.ii 
Sleep disturbance: 1.d.ii or 1.d.iii 
Speech limitation: 1.e.i 
Definition of severity indicators:  
Frequent attacks: 1. Iii or 1.iv (≥4 attacks) 
Shortness of breath: 2.i or 2.ii 
Sleep disturbance: 3.ii or 3.iii 
Interference with activities: 4.ii, 4.iii, or 4.iv 
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Table S2:  Characteristics of children excluded and included from analyses 
Characteristics 
Not included in analyses Included in analyses* 
P No surveys 1-2 surveys† All 3 surveys‡ 
n/N % n/N % n/N % 
ALSPAC N=2950  N=3641  N=7468 
  
Sex male 1506/2938 51.3 1916/3641 52.6 3844/7468 51.5 0.445 
Ethnicity white 1689/1863 90.7 3174/3329 95.3 7181/7344 97.8 <0.001 
Maternal smoking during pregnancy 979/2539 38.6 1149/3553 32.3 1542/7445 20.7 <0.001 
Older siblings (≥1) 374/620 60.3 1805/3062 58.9 3973/7212 55.1 <0.001 
Crowding, >1 person/room 177/480 36.9 822/2619 31.4 1480/6823 21.7 <0.001 
Pet ownership 283/495 57.2 1599/2745 58.3 3894/7101 54.8 0.008 
LRC N=1037 
 
N=1843 
 
N=1420 
  
Sex male 531/1037 51.2 928/1843 50.4 764/1420 53.8 0.138 
Ethnicity white 739/1037 71.3 1494/1843 81.1 1267/1420 89.2 <0.001 
Maternal smoking during pregnancy 138/457 30.2 300/1474 20.4 160/1391 11.5 <0.001 
Older siblings (≥1) 315/453 69.5 968/1437 67.4 869/1361 63.9 0.039 
Crowding, >1 person/room 253/464 54.5 666/1472 45.2 484/1380 35.1 <0.001 
Pet ownership 173/466 37.1 623/1495 41.7 603/1408 42.8 0.095 
Abbreviations: ALSPAC Avon Longitudinal Study on Parents and Children, LRC Leicestershire Respiratory Cohort 1998-b 
* Information on wheeze from at least on survey at age 2, 4, or 6 years 
† Number of surveys (age 2, 4, or 6 years) from which information on wheeze was available 
‡ P-values from  2-tests
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Table S3: Characteristics of children at age 2 years according to phenotype of wheeze  
Characteristics 
EVW MTW NCW 
P* 
n/N % n/N % n/N % 
ALSPAC N=752  N=928  N=122   
Sex male 440/752 58.5 559/928 60.2 70/122 57.4 0.698 
Ethnicity white 724/734 98.6 844/884 95.5 114/116 98.3 <0.001 
Maternal smoking during pregnancy 192/749 25.6 298/915 32.6 43/121 35.5 0.003 
Older siblings (≥1) 439/708 62.0 522/850 61.4 64/111 57.7 0.682 
Crowding, >1 person/room 144/655 22.0 251/799 31.4 45/98 45.9 <0.001 
Pet ownership 395/682 57.9 479/832 57.6 51/103 49.5 0.262 
LRC N=229 
 
N=295 
 
N=9  
 
Sex male 134/229 58.5 181/295 61.4 2/9 22.2 0.058 
Ethnicity white 203/229 88.6 259/295 87.8 8/9 88.9 0.954 
Maternal smoking during pregnancy 35/220 15.9 69/292 23.6 2/9 22.2 0.099 
Older siblings (≥1) 145/217 66.8 192/283 67.8 6/9 66.7 0.970 
Crowding, >1 person/room 95/222 42.8 135/286 47.2 4/9 44.4 0.612 
Pet ownership 98/227 43.2 107/293 36.5 2/9 22.2 0.176 
Abbreviations: ALSPAC Avon Longitudinal Study on Parents and Children, LRC Leicestershire Respiratory Cohort 1998-b, EVW episodic viral wheeze, 
MTW multiple trigger wheeze, NCW Non-classifiable wheeze 
* P-values from  c2-tests
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Table S4: Association between wheeze phenotypes and wheeze 2 years later  
Age at 
Baseline 
(years) 
Age at 
Follow-up 
(years) 
Phenotype at 
baseline 
Current wheeze at follow up 
n (%) Crude OR (95% CI) Adj. OR* (95% 
CI) 
ALSPAC          
2 4 No wheeze  681 (10.3) 1 1 
  EVW 301 (47.2) 7.8 (6.5, 9.3) 3.7 (2.9, 4.6) 
  MTW 448 (59.0) 12.5 (10.6, 14.8) 4.4 (3.5, 5.7) 
4 6 No wheeze  348 (5.4) 1 1 
  EVW 179 (40.6) 11.9 (9.5, 14.8) 3.4 (2.5, 4.7) 
  MTW 435 (60.7) 26.6 (22.2, 32.1) 4.9 (3.5, 6.8) 
LRC       
2 4 No wheeze  163 (11.1) 1 1 
  EVW 56 (31.8) 3.7 (2.6, 5.3) 2.5 (1.6, 3.9) 
  MTW 120 (55.3) 9.9 (7.2, 13.5) 4.0 (2.3, 7.1) 
4 6 No wheeze  101 (6.9) 1 1 
  EVW 36 (37.5) 8.1 (5.1, 12.8) 7.0 (4.1, 12.0) 
  MTW 131 (61.5) 21.5 (15.3, 30.3) 13.6 (7.7, 24.0) 
Abbreviations: ALSPAC Avon Longitudinal Study on Parents and Children, LRC Leicestershire Respiratory Cohort 1998-b, EVW episodic viral wheeze, 
MTW multiple trigger wheeze 
* Adjusted for symptom severity at baseline (frequent attacks, shortness of breath, sleep disturbance, interference with activities and speech limitation).
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Table S5: Association between wheeze phenotypes at baseline and 2-year follow-up 
Age at 
baseline 
(years) 
Age at 
follow-up 
(years) 
Phenotype 
at baseline 
N* 
(100 %) 
No wheeze 
at follow-up 
n (%) 
EVW at follow-up MTW at follow-up 
n (%) Crude RRR†  
(95% CI) 
Adj. RRR†‡ 
(95% CI) 
n (%) Crude RRR†‡ 
(95% CI) 
Adj RRR† 
(95% CI) 
ALSPAC           
2 4 No wheeze  6465 5934 (91.8) 237 (3.7) 1 1 294 (4.6) 1 1 
  EVW 591 337 (57.0) 126 (21.3) 9.4 (7.4, 11.9) 4.6 (3.3, 6.4) 128 (21.7) 7.7 (6.1, 9.7) 3.2 (2.3, 4.3) 
  MTW 699 311 (44.5) 73 (10.4) 5.9 (4.4, 7.8) 2.2 (1.5, 3.3) 315 (45.1) 20.5 (16.8, 24.8) 6.2 (4.6, 8.4) 
4 6 No wheeze  6271 6057 (96.6) 79 (1.3) 1 1 135 (2.2) 1 1 
  EVW 392 262 (66.8) 79 (20.2) 23.1 (16.5, 32.3) 8.0 (4.9, 13.1) 51 (13.0) 8.7 (6.2, 12.3) 2.0 (1.2, 3.3) 
  MTW 616 282 (45.8) 52 (8.4) 14.1 (9.8, 20.5) 3.3 (1.9, 6.0) 282 (45.8) 44.9 (35.4, 56.9) 6.7 (4.3, 10.4) 
LRC            
2 4 No wheeze  1461 1301 (89.1) 60 (4.1) 1 1 100 (6.8) 1 1 
  EVW 176 120 (68.2) 27 (15.3) 4.9 (3.0, 8.0) 4.1 (2.2, 7.5) 29 (16.5) 3.1 (2.0, 4.9) 1.8 (1.0, 3.2) 
  MTW 216 97 (44.9) 23 (10.7) 5.1 (3.0, 8.7) 3.3 (1.4, 7.7) 96 (44.4) 12.9 (9.1, 18.2) 4.1 (2.1, 7.9) 
4 6 No wheeze  1459 1360 (93.2) 28 (1.9) 1 1 71 (4.9) 1 1 
  EVW 95 60 (63.2) 19 (20.0) 15.4 (8.1, 29.1) 15.5 (7.3, 32.9) 16 (16.8) 5.1 (2.8, 9.3) 4.0 (2.0, 8.0) 
  MTW 213 82 (38.5) 14 (6.6) 8.3 (4.2, 16.4) 7.0 (2.6, 18.9) 117 (54.9) 27.3 (18.9, 39.6) 15.6 (8.3, 29.2) 
Abbreviations: ALSPAC Avon Longitudinal Study on Parents and Children, LRC Leicestershire Respiratory Cohort 1998-b, EVW episodic viral wheeze, 
MTW multiple trigger wheeze, RRR relative risk ratio 
* Numbers include only children with classifiable wheeze (see Table 1) or no wheeze at baseline and follow-up 
† Results from multinomial regression analysis including non-classifiable wheeze (see Table 1) but results for this category are not reported here. 
‡ Adjusted for symptom severity at baseline (frequent attacks, shortness of breath, sleep disturbance, interference with activities and speech limitation). 
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Table S6: Association between wheeze phenotypes at age 2 and wheeze at age 6 years  
Phenotype at 
baseline 
Current wheeze at follow up 
n (%) Crude OR 
(95% CI) 
Adj. OR* (95% 
CI) 
ALSPAC      
No wheeze  461 (7.7) 1 1 
EVW 177 (30.5) 5.3 (4.3, 6.4) 2.4 (1.9, 3.2) 
MTW 277 (42.3) 8.8 (7.3, 10.6) 2.9 (2.2, 3.9) 
LRC     
No wheeze  105 (8.6) 1 1 
EVW 44 (28.2) 4.2 (2.8, 6.2) 2.4 (1.4, 4.0) 
MTW 78 (42.6) 7.9 (5.5, 11.2) 3.0 (1.5, 5.8) 
Abbreviations: ALSPAC Avon Longitudinal Study on Parents and Children, LRC Leicestershire Respiratory Cohort 1998-b, EVW episodic viral wheeze, 
MTW multiple trigger wheeze 
* Adjusted for symptom severity at baseline (frequent attacks, shortness of breath, sleep disturbance, interference with activities and speech limitation).
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Table S7: Association between wheeze phenotypes at age 2 and age 6 years 
Abbreviations: ALSPAC Avon Longitudinal Study on Parents and Children, LRC Leicestershire Respiratory Cohort 1998-b, EVW episodic viral wheeze, 
MTW multiple trigger wheeze 
* Numbers include only children with classifiable wheeze (see Table 1) or no wheeze at baseline and follow-up 
† Results from multinomial regression analysis including non-classifiable wheeze (see Table 1) but results for this category are not reported here. 
‡ Adjusted symptom severity at baseline (frequent attacks, shortness of breath, sleep disturbance, interference with activities and speech limitation). 
Phenotype 
at baseline 
N* 
(100 %) 
No wheeze at 
follow-up 
 n (%) 
EVW at follow-up MTW at follow-up 
n (%) Crude RRR† 
(95% CI) 
Adj. RRR†‡ 
(95% CI) 
n (%) Crude RRR†  
(95% CI) 
Adj. RRR†‡ 
(95% CI) 
ALSPAC                
No wheeze  5854 5539 (94.6) 108 (1.8) 1 1 207 (3.5) 1 1 
EVW 532 403 (75.8) 63 (11.8) 8.0 (5.8, 11.1) 3.2 (2.0, 5.2) 66 (12.4) 4.4 (3.3, 5.9) 1.7 (1.2, 2.6) 
MTW 585 378 (64.6) 34 (5.8) 4.6 (3.1, 6.9) 1.3 (0.7, 2.4) 173 (29.6) 12.2 (9.8, 15.4) 3.4 (2.3, 5.1) 
LRC          
No wheeze  1212 1111 (91.7) 28 (2.3) 1 1 73 (6.0) 1 1 
EVW 156 112 (71.8) 22 (14.1) 7.8 (4.3, 14.1) 4.6 (2.0, 10.3) 22 (14.1) 3.0 (1.8, 5.0) 1.6 (0.8, 3.2) 
MTW 183 105 (57.4) 8 (4.4) 3.0 (1.3, 6.8) 1.4 (0.4, 4.9) 70 (38.2) 10.1 (6.9, 14.9) 3.6 (1.7, 7.7) 
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Table S8: Association between the indirect classification of wheeze phenotypes used in analyses, 
and parent’s direct classification* into episodic and chronic wheeze in the LRC at age 6 years 
MTW and EVW 
defined as in 
Table 1. 
Episodic wheeze* Chronic 
wheeze* 
Total P-value 
Fisher’s 
exact test n (Row %) n Row % n Row % 
Wheeze at 2 years 
EVW 226 (99) 3 (1) 229 (100) <0.001 
MTW 222 (77) 68 (23) 290 (100)  
Wheeze at 4 years 
EVW 153 (99) 2 (1) 155 (100) <0.001 
MTW 267 (80) 68 (20) 335 (100)  
Wheeze at 6 years 
EVW 76 (97) 2 (3) 78 (100) <0.001 
MTW 189 (78) 52 (22) 241 (100)  
* Based on parents’ response to the following questions: “Which of these two descriptions fits best 
your child’s wheeze? 1) My child has only short attacks of wheeze, for example with colds. In 
between these attacks, he/she does not normally wheeze. 2) My child wheezes always or a lot of the 
time. With colds he/she has attacks with more severe wheeze”. Episodic and chronic wheeze are 
defined as responses 1 and 2 respectively. 
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Table S9: Studies on the stability of EVW and MTW 
 Study population, age at 
baseline 
Follow-
up 
period 
Phenotype definition Baseline Phenotype at follow-up* Percentage among 
children with wheeze 
at follow-up† 
Study    N no wheeze n 
(%) 
EVW n 
(%) 
MTW n 
(%) 
EVW % MTW % 
Studies on the stability of EVW (N = number of children with EVW at baseline) 
Present study  2 years        
ALSPAC 2-4 
years 
Population-based cohorts, 
2.5 years 
 EVW: Wheeze triggered by infection or 
bronchitis 
MTW: Wheeze triggered by smoke, weather, 
allergens, air pollution, other 
591 337 (57) 126 (21) 128 (22) 126 (50) 128 (50) 
ALSPAC 4-6 
years 
   392 262 (67) 79 (20) 51 (13) 79 (61) 51 (39) 
LRC 2-4 years Population-based cohorts, 2 
years 
 EVW: Wheeze during or soon after a cold. 
MTW: Wheeze without cold and wheeze 
triggered by ecercise, excitement, allergens 
176 120 (68) 27 (15) 29 (17) 27 (48) 29 (52) 
LRC 4-6 years    95 60 (63) 19 (20) 16 (17) 19 (54) 16 (46) 
Kapelle 20121 Treated for wheeze at 
hospital, 1.9 years (median) 
Min. 2 
years 
EVW: Wheeze only during viral colds. MTW: 
Wheeze during viral colds as well as smoke, 
fog or allergens. 
78 36 (47) 23 (29) 19 (24) 23 (55) 19 (45) 
Topal 20132 Children hospitalized for 
wheeze, 2 years (median) 
20 
months 
EVW: Wheeze only by infections, no wheeze 
between. 
236 91 (38) 108 (46) 37 (16) 108 (74) 37(26) 
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MTW: Wheeze triggered by colds as well as 
allergens, smoke, exercise or weather 
Van Wonderen 
20153 
Children visiting physician 
because of cough or 
wheeze, 2 years (median) 
1 year EVW: Wheeze with colds but not between 
colds, past 12 months. MTW: Wheeze with 
colds and also between, past 12 months 
      
Baseline to 12 mo    126 50 (40) 67 (53) 9 (7) 67 (88) 9 (12) 
Baseline to 24 mo    126 86 (68) 33 (26) 7 (6) 33 (83) 7 (17) 
Schultz 2009 Children diagnosed with 
asthma, 4 years (median) 
1 year EVW: Wheezing only during colds and not in 
the absence of colds. MTW: Wheeze in the 
absence of colds, irrespective of wheeze with 
colds 
38 13 (34) 12 (32) 13(34) 12 (48) 13(52) 
Studies on the stability of MTW (N = number of children with MTW at baseline) 
Present study  2 years        
ALSPAC 2-4 
years 
Population-based cohorts, 
2.5 years 
 EVW: Wheeze triggered by infection or 
bronchitis 
MTW: Wheeze triggered by smoke, weather, 
allergens, air pollution, other 
699 311 (45) 73 (10) 315 (45) 73 (19) 315 (81) 
ALSPAC 4-6 
years 
   616 282 (46) 52 (8) 282 (46) 52 (16) 282 (84) 
LRC 2-4 years Population-based cohorts, 2 
years 
 EVW: Wheeze during or soon after a cold. 
MTW: Wheeze without cold and wheeze 
triggered by ecercise, excitement, allergens 
216 97 (45) 23 (11) 96 (44) 23 (19) 96 (81) 
LRC 4-6 years    213 82 (39) 14 (7) 117 (55) 14 (11) 117 (89) 
39 
 
Van Wonderen 
20153 
Children visiting physician 
because of cough or 
wheeze, 2 years (median) 
1 year EVW: Wheeze with colds but not between 
colds, past 12 months. MTW: Wheeze with 
colds and also between, past 12 months 
      
Baseline to 12 mo    49 13 (27) 14 (29) 22 (45) 14 (39) 22 (61) 
Baseline to 24 mo    49 24 (49) 14 (29) 11 (22) 14 (56) 11 (44) 
Schultz 20094 Children diagnosed with 
asthma, 4 years (median) 
1 year EVW: Wheezing only during colds and not in 
the absence of colds. MTW: Wheeze in the 
absence of colds, irrespective of wheeze with 
colds 
71 11 (16) 22 (31) 38 (54) 22 (37) 38 (63) 
*  Numbers and percentage (parenthesis) of children with no wheeze, EVW, and MTW at follow-up among children with the given baseline phenotype 
(100%). 
† Numbers and percentage (parenthesis) of children with EVW, and MTW at follow-up among children with the given baseline phenotype who continued to 
wheeze at follow-up (non-wheezers at follow-up excluded). 
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